Orthovita in Conjunction with Canaccord Adams will Conduct an Institutional Investors Meeting on Friday, September 14th, in Boston

Orthovita, Inc. (NASDAQ: VITA), a spine and orthopedic biosurgery company, announced today that it will conduct an institutional investor meeting in conjunction with Canaccord Adams Inc. on Friday, September 14, 2007 in Boston, MA. Antony Koblish, President and Chief Executive Officer of Orthovita, Albert J. Pavucek, Jr., Chief Financial Officer, and several members of Orthovita’s management team will present at the meeting scheduled from 10:00 a.m. to 2:00 p.m. Eastern Time, in the Griffin/Robinson Room of The InterContinental Hotel, 510 Atlantic Avenue, Boston, MA. William J. Plovanic, CFA, managing director, equity research from Canaccord Adams will be co-hosting the meeting. In addition, the meeting will feature guest speaker H. Paul Hatten, Jr., M.D., from Indian River Radiology of Vero Beach, Florida, who will give a presentation entitled "Treatment of Osteoporotic VCF with CORTOSS®: Preliminary Results and Biomechanical Considerations from the First Prospective Trial at a Single Institution”, at approximately 11:00 a.m. Eastern Time and will cover part of a prospective randomized controlled study being conducted under an FDA Investigational Device Exemption (IDE). The study assesses the safety and efficacy of Orthovita’s CORTOSS compared to commercially available PMMA bone cements in osteoporotic compression fractures of the vertebra(e). A total of 256 patients have been enrolled at 19 sites using a 2:1 randomization with 162 patients assigned to CORTOSS and 94 patients assigned to PMMA. Dr. Hatten is one of the 19 clinical sites involved in the FDA Investigational Device Exemption (IDE) study and will cover part of a prospective randomized controlled study being conducted under an FDA IDE study. At the Indian River Radiology site, 57 patients have been enrolled; 36 treated using CORTOSS and 21 treated using PMMA bone cement. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS® Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-based bone material, and VITAGEL® Surgical Hemostat, which is an adherent matrix and an impermeable barrier to blood flow. Our longer-term U.S. clinical development program is focused on our internally developed CORTOSS® Bone Augmentation Material technology platform, which is primarily designed for injections in osteoporotic spines to treat vertebral compression fractures. We work jointly with Kensey Nash Corporation to develop and commercialize novel synthetic-based biomaterial products, we market VITAGEL under a license granted by Angiotech Pharmaceuticals, Inc., and we continue to pursue similar relationships with other companies in biomaterials. Disclosure Notice This press release may contain forward-looking statements regarding Orthovita’s current expectations of future events that involve risks and uncertainties, including, without limitation, the development, regulatory approval, demand and market acceptance of our products; the development of our sales network; the adequacy of inventory; our ability to manufacture products; timing of any submissions to the FDA related to CORTOSS approval; the adequacy of available resources; and other aspects of our business. Such statements are based on management’s current expectations and are subject to a number of substantial risks and uncertainties that could cause actual results or timeliness to differ materially from those addressed in the forward-looking statements. Factors that may cause such a difference are listed from time to time in reports filed by the Company with the U.S. Securities and Exchange Commission (SEC), including but not limited to risks described in our most recently filed Form 10-K under the caption "Risks Factors”. Further information about these and other relevant risks and uncertainties may be found in Orthovita’s filings with the SEC, all of which are available from the SEC as well as other sources. Orthovita undertakes no obligation to publicly update any forward-looking statements.